This document announces the initiation of Prexton Therapeutics’ first-in-human clinical trial with an mGluR4 positive allosteric modulator (PAM), a pioneering therapeutic approach for Parkinson’s disease. Conducted in 2016, this Phase I trial evaluates the safety, tolerability, and pharmacological profile of the compound in 72 healthy volunteers through ascending oral doses, with results expected later that year.

Unlike conventional dopaminergic therapies, Prexton’s innovative compound stimulates a compensatory neuronal system unaffected by Parkinson’s disease. By modulating the glutamatergic system, this first-in-class molecule aims to alleviate motor complications while minimizing adverse effects, potentially offering patients a more favorable benefit/risk profile compared to existing treatments.

The company’s strategy focuses on developing a portfolio of novel mGluR4-targeting molecules supported by compelling preclinical efficacy data. The Phase I trial marks a critical step toward validating this approach and advancing to later-stage studies designed to demonstrate clinical effectiveness.

Prexton’s progress is backed by experienced CNS researchers and supported through a $10 million (€8.86m) Series A funding round completed in 2015. This milestone strengthens Prexton’s position as a leader in mGluR4 drug development for Parkinson’s disease.